Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLEX-MRA: Flexible use of finerenone in HF with mildly reduced/preserved EF and CKD
jRCTs031260070Recruiting
- Sponsor
- Bayer
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finerenone in heart failure (HF) and chronic kidney disease (CKD), sponsored by Bayer. Primary endpoint: Absolute change in serum potassium levels. Started May 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs031260070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260070.